G42 Healthcare announces partnership with WHOOP
Mita Srinivasan
10X Technology

G42 Healthcare announces partnership with WHOOP

Whoop4Humanity initiative enables volunteers to check daily health and well-being parameters for vaccine trials

Abu Dhabi-based G42 Healthcare has partnered with Boston-based wearable technology firm, WHOOP, for the Whoop4Humanity initiative that offers volunteers participating in the Phase III trials of the COVID-19 vaccine the opportunity to benefit from a 24/7 fitness and health monitor to measure key biometrics. This is the first trial of its kind to feature wearable technology and will include thousands of volunteers who are participating in the trials.

The Whoop4Humanity initiative ensures that volunteers who now join the clinical trials at ADNEC in Abu Dhabi and the Al Qarain Center in Sharjah, including those coming in for the second dose, can further enhance their participation in the trails by using the new wearable devices which will enable them to check their daily heart rate, respiratory rate, heart rate variability, sleep performance, and more.

Commenting on the new partnership, G42 Healthcare CEO, Ashish Koshy, said: "As a digital business, this new partnership is a logical extension of the highly-advanced AI and super computer solutions we are already using in the trials process. New volunteers will be invited to engage with the technology developed by WHOOP to enhance their individual volunteer experience and contribute to the advanced research involved in these sophisticated trials.”

G42 Healthcare believes that WHOOP can be a powerful tool to boost the comprehensive volunteer healthcare management program by helping thousands of vaccine volunteers to self-monitor their well-being while measuring their fitness, sleep, and recovery levels during the trials. WHOOP provides valuable insights and actionable feedback around specific markers, thus encouraging better decision making for volunteers' health and contributing to the trials' overall success.

The trials began in Abu Dhabi on 16th July and are being managed by G4 Healthcare in partnership with the Department of Health - Abu Dhabi, the UAE Ministry of Health and Prevention (MOHAP) and Abu Dhabi Health Services Company (SEHA). They are being conducted following the international guidelines stipulated by the World Health Organization (WHO) and the United States Food & Drug Administration (USFDA).